Cardiology Leader Dr. Deepak L. Bhatt

Josh Pirtle
|
Sep 17, 2020

Dr. Deepak L. Bhatt is a renowned physician, instructor, and keynote speaker who specializes in interventional cardiology and cardiovascular medicine. He is currently the executive director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital while teaching medicine at Harvard Medical School. Additionally, he is listed as a trustee of the American College of Cardiology.

Education and Early Career

With an impressive scholarly background, Dr. Deepak L. Bhatt was valedictorian at Boston Latin School before going on to achieve great things in his medical education and career. He first attended MIT, Massachusetts Institute of Technology and obtained his undergraduate science degree as a National Merit Scholar. While at MIT, Dr. Bhatt served as a research associate at Harvard Medical School.  

For his Masters and Doctorates, he went on to Cornell University and focused his studies in Public Health with a concentration in clinical effectiveness from Harvard University. He interned at the Hospital of the University of Pennsylvania for his residency program, and then obtained cardiovascular training at Cleveland Clinic. 

Upon completion of his residency, Bhatt was selected as the Chief of Cardiology at VA Boston Healthcare Systems, where he served for several years.

Research and Clinical Trials

With a total of 53 medical trials in his career, Dr. Deepak L. Bhatt MD MDH has blazed a trail for future researchers to traverse. He currently has 11 medical trials active, and has completed 36 to date. His focus relates to cardiovascular disease and cardiovascular patient care.

REDUCE-IT

Dr. Deepak discussed the REDUCE-IT trial live at the American Heart Association 2018 event, and went into further detail with the New England Journal of Medicine. He states REDUCE-IT “has the greatest potential to be practice-changing and paradigm-shifting.” The trial randomized 8,000 patients with triglycerides between 135 and 150 mg/dL and had additional cardiovascular risks to receive either four grams per day of icosapent ethyl (the study drug) or a placebo. Icosapent ethyl is a highly-purified EPA, and the study has shown dramatic results with only four grams per day.

The study had followed patients for five years at the last update of trial outcomes. The findings and updates of the trial established the safety of icosapent ethyl given as a cardiovascular reducing drug and established a large degree of efficacy. Thanks to this study, we have seen a “large degree of benefits across multiple endpoints,” Dr. Deepak told the New England Medicine Journal.

CHARISMA

Dr. Deepak L. Bhatt was the principal investigator for the CHARISMA clinical trial, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance. The objective of the study was to prevent cardiovascular morbidity/mortality. The study drug, clopidogrel, was compared with a placebo to measure its efficacy in preventing major complications such as stroke, heart attack, and cardiovascular death. The study ran from December 23, 2002, and was last updated in April of 2012. 

Thanks to the research of Dr. Deepak L. Bhatt and his team, clopidogrel plus aspirin was not found to benefit patients more than aspirin alone in reducing the rate of mortality from cardiovascular issues, myocardial infarction, and stroke. While the study results imply that the study drug may pose additional risk to patients, and cause more harm than positive results. 

Publications

With over 750 peer-reviewed publications, Dr. Bhatt is a key resource for cardiologists. He is noted as a Thomson Reuters Highly Cited Researcher. His work focuses on giving cardiac patients better care, and reducing the risks of heart medications for patients. 

The American Heart Association cites his work frequently, and listed three of his 2014 works in their American Stroke Association Top Ten Advances in Heart Disease and Stroke Research.

His vast cardiac knowledge led to becoming the editor of Cardiovascular Intervention: A Companion to Braunwald’ Heart Disease, which is a medical reference book used by cardiologists the world over. The book’s goal is to help connect cardiologists with new technologies and breakthroughs that will elevate the level of care their patients receive. 

Social Media Presence

In early January, his research for the REDUCE-IT trial got people talking on LinkedIn when he shared his multi-authored piece from European Heart Journal titled “Profound Reductions in First and Total Cardiovascular Events With Icosapent Ethyl in The REDUCE-IT Trial: Why These Results Usher In A New Era In Dyslipidaemia Therapeutics.” Dr. Irving Loh (TEDx speaker and chair of the American College of Cardiology) wrote on LinkedIn when sharing the article, “A citable reference for colleagues who ask us (lipidologists, preventive cardiologists, endocrinologists, primary care professionals) if elevated triglycerides matter and if treatment favorably impacts outcomes.”

Dr. Deepak L. Bhatt is seen as a reputable source far and wide in the healthcare industry, with over 16,000 mentions on social media, and nearly 80,000 citations for his research and articles. His colleagues hold his research and analysis in high esteem, and are quick to share his findings. Cardiologists are linking to his social media posts to find better solutions and outcomes for their cardiac patients, and see him as a leader in cardiac advancements. 

Awards and Grants Received:

Dr. Deepak L. Bhatt has received numerous accolades from top Cardiology resources since his early career, and continues to be a leader to this day.

Best Doctors in America - 2005 to 2018

Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s Hospital - 2017

ACC’s Distinguished Mentor Award in 2018

ACC.org Top Ten Clinical Trials (for REDUCE-IT, EVAPORATE, and DECLARE-TIMI 58) 2019  from American

College of Cardiology

Boston Magazine Top Doctor, 2019

Castle Connolly America's Top Doctors, 2019

AHA Council on Lifestyle and Cardiometabolic Health's Most Impactful Publications – 2018 & 2019

American Heart Association Distinguished Scientist Award 2019

Castle Connolly Top Doctor, Interventional Cardiology 2019

Clarivate Analytics Web of Science Highly Cited Researcher 2019

Top Heart Disease and Stroke Research Advances 2019, honor issuer American Heart Association For FDA label expansion of icosapent ethyl based on REDUCE-IT

H1 looks forward to seeing advancements in the care of cardiac patients thanks to the research and development of new methods brought forth by Dr. Deepak L. Bhatt. His current trials and future research are changing the way we approach heart health, and improving the lives of cardiac patients.